EGFR and neoplasm: However, binding of the dodecavalent LC/HC-scTRAIL to EGFR and TRAIL receptors on EGFR+ tumour cells was shown to be similar compared to hexavalent formats, suggesting a rather stronger reduction of bioactivity than observed upon competition with cetuximab.